A Phase I study of capecitabine, carboplatin, and paclitaxel with external beam radiation therapy for esophageal carcinoma

International Journal of Radiation Oncology Biology Physics

Volumn 67, Issue 4, 2007, Pages 1002-1007

  Czito, Brian G ^a   Kelsey, Chris R ^a   Hurwitz, Herbert I ^a   Willett, Chris G ^a   Morse, Michael A ^a   Blobe, Gerard C ^a   Fernando, Nishan H ^a   D'Amico, Thomas A ^a   Harpole, David H ^a   Honeycutt, Wanda ^a   Yu, Daohai ^a   Bendell, Johanna C ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Capecitabine; Carboplatin; Esophageal cancer; Paclitaxel; Radiation therapy

Indexed keywords

CELLS; DRUG PRODUCTS; PATIENT TREATMENT; RADIOTHERAPY; TOXICITY; TUMORS;

CAPECITABINE; CARBOPLATIN; ESOPHAGEAL CANCER; PACLITAXEL;

CHEMOTHERAPY;

CAPECITABINE; CARBOPLATIN; PACLITAXEL;

ADULT; AGED; ANEMIA; ANOREXIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER STAGING; CLINICAL ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DEHYDRATION; DIARRHEA; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG TOLERABILITY; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGITIS; ESOPHAGOGRAPHY; ESOPHAGUS CARCINOMA; ESOPHAGUS RESECTION; EXTERNAL BEAM RADIOTHERAPY; FATIGUE; FEMALE; HUMAN; HYPERTENSION; HYPOTENSION; LUNG EMBOLISM; MALE; MAXIMUM TOLERATED DOSE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA; THROMBOCYTOPENIA; TREATMENT INDICATION; TREATMENT OUTCOME; TREATMENT RESPONSE; VOMITING;

ADENOCARCINOMA; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AREA UNDER CURVE; CARBOPLATIN; CARCINOMA, SQUAMOUS CELL; COMBINED MODALITY THERAPY; DEOXYCYTIDINE; ESOPHAGEAL NEOPLASMS; FEMALE; FLUOROURACIL; HUMANS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; PACLITAXEL; RADIOTHERAPY DOSAGE;

EID: 33847302490     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2006.10.027     Document Type: Article

References (27)

1. Cooper J.S., Guo M.D., Herskovic A., et al. Chemoradiotherapy of locally advanced esophageal cancer: Long-term follow-up of a prospective randomized trial (RTOG 85-01). Radiation Therapy Oncology Group. JAMA 281 (1999) 1623-1627
2. Minsky B.D., Pajak T.F., Ginsberg R.J., et al. INT 0123 (Radiation Therapy Oncology Group 94-05): Phase III trial of combined-modality therapy for esophageal cancer: High-dose versus standard-dose radiation therapy. J Clin Oncol 20 (2002) 1167-1174
3. Walsh T.N., Noonan N., Hollywood D., et al. A comparison of multimodal therapy and surgery for esophageal adenocarcinoma. N Engl J Med 335 (1996) 462-467
4. Bosset J.F., Gignoux M., Triboulet J.P., et al. Chemoradiotherapy followed by surgery compared with surgery alone in squamous-cell cancer of the esophagus. N Engl J Med 337 (1997) 161-167
5. Burmeister B.H., Smithers B.M., Gebski V., et al. Surgery alone versus chemoradiotherapy followed by surgery for resectable cancer of the oesophagus: A randomised controlled phase III trial. Lancet Oncol 6 (2005) 659-668
6. Kelsen D.P., Ginsberg R., Pajak T.F., et al. Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer. N Engl J Med 339 (1998) 1979-1984
7. Stahl M., Stuschke M., Lehmann N., et al. Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus. J Clin Oncol 23 (2005) 2310-2317
8. Urba S.G., Orringer M.B., Turrisi A., et al. Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma. J Clin Oncol 19 (2001) 305-313
9. Jatoi A., Martenson J., Mahoney M.R., et al. Results of a planned interim toxicity analysis with trimodality therapy, including carboplatin AUC = 4, paclitaxel, 5-fluorouracil, amifostine, and radiation for locally advanced esophageal cancer: Preliminary analyses and treatment recommendations from the North Central Cancer Treatment Group. Int Semin Surg Oncol 1 (2004) 9
10. Meluch A.A., Greco F.A., Gray J.R., et al. Preoperative therapy with concurrent paclitaxel/carboplatin/infusional 5-FU and radiation therapy in locoregional esophageal cancer: Final results of a Minnie Pearl Cancer Research Network phase II trial. Cancer J 9 (2003) 251-260
11. Seung S.K., Smith J.W., Molendyk J., et al. Selective dose escalation of chemoradiotherapy for esophageal cancer: Role of treatment intensification. Semin Oncol 31 (2004) 13-19
12. Brenner B., Ilson D.H., Minsky B.D., et al. Phase I trial of combined-modality therapy for localized esophageal cancer: Escalating doses of continuous-infusion paclitaxel with cisplatin and concurrent radiation therapy. J Clin Oncol 22 (2004) 45-52
13. Goldberg M., Farma J., Lampert C., et al. Survival following intensive preoperative combined modality therapy with paclitaxel, cisplatin, 5-fluorouracil, and radiation in resectable esophageal carcinoma: A phase I report. J Thorac Cardiovasc Surg 126 (2003) 1168-1173
14. Henry L.R., Goldberg M., Scott W., et al. Induction cisplatin and paclitaxel followed by combination chemoradiotherapy with 5-fluorouracil, cisplatin, and paclitaxel before resection in localized esophageal cancer: A phase II report. Ann Surg Oncol 13 (2006) 214-220
15. Weiner L.M., Colarusso P., Goldberg M., et al. Combined-modality therapy for esophageal cancer: Phase I trial of escalating doses of paclitaxel in combination with cisplatin, 5-fluorouracil, and high-dose radiation before esophagectomy. Semin Oncol 24 (1997) S19-93-S19-95
16. Walshe L.J., Malak S.F., Eagan J., et al. Complication rates among cancer patients with peripherally inserted central catheters. J Clin Oncol 20 (2002) 3276-3281
17. Gaspar L.E., Winter K., Kocha W.I., et al. A phase I/II study of external beam radiation, brachytherapy, and concurrent chemotherapy for patients with localized carcinoma of the esophagus (Radiation Therapy Oncology Group Study 9207). Final report. Cancer 88 (2000) 988-995
18. Le Prise E., Etienne P.L., Meunier B., et al. A randomized study of chemotherapy, radiation therapy, and surgery versus surgery for localized squamous cell carcinoma of the esophagus. Cancer 73 (1994) 1779-1784
19. Tepper J.E., Krasna M., Niedzwiecki D., et al. Superiority of trimodality therapy to surgery alone in esophageal cancer: Results of CALGB 9781. J Clin Oncol 24 18 Suppl (2006) 4012
20. Medical Research Council Oesophageal Cancer Working Group. Surgical resection with or without preoperative chemotherapy in oesophageal cancer: A randomised controlled trial. Lancet 359 (2002) 1727-1733
21. Ilson D.H., Ajani J., Bhalla K., et al. Phase II trial of paclitaxel, fluorouracil, and cisplatin in patients with advanced carcinoma of the esophagus. J Clin Oncol 16 (1998) 1826-1834
22. Ilson D.H., Forastiere A., Arquette M., et al. A phase II trial of paclitaxel and cisplatin in patients with advanced carcinoma of the esophagus. Cancer J 6 (2000) 316-323
23. Ajani J.A., Komaki R., Putnam J.B., et al. A three-step strategy of induction chemotherapy then chemoradiation followed by surgery in patients with potentially resectable carcinoma of the esophagus or gastroesophageal junction. Cancer 92 (2001) 279-286
24. Urba S.G., Orringer M.B., Ianettonni M., et al. Concurrent cisplatin, paclitaxel, and radiotherapy as preoperative treatment for patients with locoregional esophageal carcinoma. Cancer 98 (2003) 2177-2183
25. Ilson D.H., Ajani J., Bhalla K., et al. Phase II trial of paclitaxel, fluorouracil, and cisplatin in patients with advanced carcinoma of the esophagus. J Clin Oncol 16 (1998) 1826-1834
26. Cunningham D., Rao S., Starling N., et al. Randomised multicentre phase III study comparing capecitabine with fluorouracil and oxaliplatin with cisplatin in patients with advanced oesophagogastric (OG) cancer: The REAL 2 trial. J Clin Oncol 24 18S (2006) LBA4017
27. Czito B.G., Willett C.G., Bendell J.C., et al. Increased toxicity with gefitinib, capecitabine, and radiation therapy in pancreatic and rectal cancer: Phase I trial results. J Clin Oncol 24 (2006) 656-662